Table 3.
Key baseline demographics for the clinical trials
| Demographic | Phase 2 trial | Phase 3 trial | ||
|---|---|---|---|---|
| Dextromethorphan-bupropion (n = 43) | Bupropion (n = 37) | Dextromethorphan-bupropion (n = 156) | Placebo (n = 162) | |
| Age (yr) | 37.3 ± 12.0 | 37.7 ± 11.9 | 42.1 ± 12.8 | 41.2 ± 13.8 |
| Female | 25 (58.1) | 26 (70.3) | 95 (60.9) | 117 (72.2) |
| Race | ||||
| White | 30 (69.8) | 20 (54.1) | 84 (53.8) | 92 (56.8) |
| Black or African American | 12 (27.9) | 14 (37.8) | 58 (37.2) | 54 (33.3) |
| Asian | 1 (2.3) | 0 | 9 (5.8) | 8 (4.9) |
| Other | 0 | 3 (8.1) | 2 (1.3) | 6 (3.7) |
| Hispanic or Latino | 6 (14.0) | 11 (29.7) | - | - |
| MADRS total score | 31.8 ± 4.0 | 32.2 ± 4.5 | 33.6 ± 4.4 | 33.2 ± 4.4 |
Values are presented as mean ± standard deviation or number (%).
MADRS, Montgomery–Åsberg Depression Rating Scale.